Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

NCT04807972 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Pancreatic Cancer

Interventions

DRUG: ABBV-927
DRUG: Budiglimab
DRUG: modified FOLFIRINOX

Sponsor

AbbVie